Profile of Adverse Drug Reactions in TB Patients Taking ATT

Title: Profile of Adverse Drug Reactions in TB Patients Taking ATT

Authors: Dr Aashutosh Asati, Dr Manoj Indurkar

DOI: https://dx.doi.org/10.18535/jmscr/v4i12.48

Abstract

INTRODUCTION- Tuberculosis treatment need more than one drug combination to eradicate tuberculosis bacteria.²The use of multidrug regimens has been associated with increased incidence of adverse drug reactions of anti-tubercular drugs. Hence, there is a need to monitor the adverse effects of antitubercular drugs in a hospital set up.

METHODOLOGY- Information on any past or current occurrence of adverse effects due to the ATT drugs being administered to the patients was collected. Frequency distribution tables were prepared from the collected data.

RESULTS AND DISCUSSION- In our study Gastrointestinal symptoms like Anorexia, Vomiting, Nausea, abdominal pain were the most commonly reported ADRs followed by headache and tingling and burning sensation in hands and feet. Similar adverse effects were reported in other studies. Adverse drug reactions were more frequently and more severely reported among females and elderly patients (>60yrs).

CONCLUSION- Adverse drug reactions among patients taking anti tubercular treatment is common, So identification of such adverse effect and prompt management will definitely be very helpful for a successful anti tubercular chemotherapy.

References

1. TB india 2016 Revised National TB Control Programme Annual Status Report. New Delhi: Central TB Division, Direct-orate General of Health and Family Welfare, Nirman Bhavan; 2011. Available from: http://www.tbcindia.nic.in/showfile.-php?lid=318.

2. WHO. Treatment of tuberculosis Guidelines. In. 4th Edition ed: World Health Organization; 2010.

3. Banu Eris- Gulbay OUG, Oznur Akkoca Yıldız, Zeynep Pınar Onen, Ferda Oner Erkekol, Ayse Baccıoglu, Turan Acıcan. Side effects due to primary antituber-culosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Journal Respiratory Medicine 2006;100:1834-42.

4. Gholami, K., E. Kamali, M.I. Hajiabdobaghiand and G. Shalviri. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharmacy Practice. 2006;4: 134-138.

5. Koju. D, B.S. Rao , B. Shrestha, R. Shakya, R. Makaju. Occurrence of side effects from anti tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu University J. Science, Engineering and Technol. 2005;1:1-8.

6. Nader, L.A., A.A. Mattos, P.D. Picon, S.L. Bassanesi, A.Z. Mattos and M.P. Rodrig-uez. Hepatotoxicity due to rifampicin, isoniazid and. pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor ?. Annals of Hepatol. 2010;9:70-4.

7. Xia, Y.Y., D.Y. Hu, F.Y. Liu, X.M. Wang, Y.L. Yuan and D.H Tu. Design of the anti-tuberculosis drugs induced adverse reactions in China national Tuberculosis prevention and cotroscheme study. BMC Public Health. 2010;10: 267-76.

8. Rahman MM, Mishuk A, Halder S, Kabir AKL. Comparative Analysis of Adverse drug Reactions in Directly Observed Treatment Short Course (DOTS) in TB Patients. Global Journal of Medical research. 2013;6:6-10.

9. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008;86:B-D.

10. Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004;4:68.

11. Nishant P. Dalal, Yogita S. Karandikar, Vijaya A. Pandit. Safety evaluation of directly observed treatment short course (DOTS) regimen in a tertiary care hospital, Pune. Int J Basic Clin Pharmacol. 2014;3:369-76.

12. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first‑line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472‑7.

13. Shakya R, Rao BS, Shrestha B. Management of antitubercular drugs-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal. Kathmandu Univ Med J (KUMJ) 2005; 3: 45-9.

14. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-9.

15. Wilson K. Sex‑related difference in drug disposition in man. Clin Pharmacokinet 1984;9:189‑202.

16. Daphne Y, Marthe P et al., Incidence of serious side effects from First-line antituberculosis drugs among patients treated for Active Tuberculosis, Am J Resp Crit Care Med. 2003;167:1472-1477.

Corresponding Author

Dr Aashutosh Asati

Department of Pulmonary Medicine, S.S.M.C Rewa